An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

An early analysis of cost-utility of baroreflex activation therapy in advanced chronic heart failure in Germany

Abstract Background This study aimed to evaluate cost-utility of baroreflex activation therapy (BAT) using the Barostim neo™ device (CVRx Inc., Minneapolis, MN, USA) compared with optimized medical management in patients with advanced chronic heart failure (NYHA class III) who were not eligible for...

Full description

Bibliographic Details
Main Authors: Oleg Borisenko, Jochen Müller-Ehmsen, JoAnn Lindenfeld, Erik Rafflenbeul, Christian Hamm
Format: Article
Language:English
Published: BMC 2018-08-01
Series:BMC Cardiovascular Disorders
Subjects:
Baroreflex activation therapy
Barostim
Cost-utility
Health economics
Markov modeling
Germany
Online Access:http://link.springer.com/article/10.1186/s12872-018-0898-x

Internet

http://link.springer.com/article/10.1186/s12872-018-0898-x

Similar Items